Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M
Shalvata Mental Health Center, Kupat-Holim, Hod Hasharon, Israel.
Biol Psychiatry. 1994 Jan 1;35(1):22-6. doi: 10.1016/0006-3223(94)91162-2.
Twenty-eight residual schizophrenics hospitalized in a chronic institution with a 9 to 30 year history of disease, with predominantly negative symptoms were given carbamazepine. Carbamazepine was administered in a double-blind trial and therapeutic effects were measured by the Scale for the Assessment of Negative Symptoms (SANS). Patients were also assessed for positive symptoms using the Brief Psychiatric Rating Scale (BPRS), for depression using the Hamilton Depression Scale, for extrapyramidal symptoms by the Simpson and Angus scale, to rule out these symptoms as sources of secondary negative symptoms. The study continued for 7 weeks with therapeutic carbamazepine levels achieved during the last 5 weeks. There was no significant positive effect of carbamazepine on negative symptoms.
28名在慢性机构住院的残留型精神分裂症患者，病程为9至30年，主要表现为阴性症状，接受了卡马西平治疗。卡马西平采用双盲试验给药，治疗效果通过阴性症状评定量表（SANS）进行测量。还使用简明精神病评定量表（BPRS）评估患者的阳性症状，使用汉密尔顿抑郁量表评估抑郁情况，通过辛普森和安格斯量表评估锥体外系症状，以排除这些症状作为继发性阴性症状的来源。该研究持续7周，在最后5周达到了卡马西平的治疗水平。卡马西平对阴性症状没有显著的积极效果。
